Pharmascience, founded in 1983, is a manufacturer of high quality generic products. Our fully integrated Canadian specialty division, Pendopharm, is a leader in commercializing innovative and value-added medicines that address unmet medical needs across key therapeutic areas. With an impressive annual production of over 5 billion doses and distribution spanning more than 50 countries, we offer 1,300 distinct high-quality products in various dosage forms. Additionally, our services extend to sterile injectable CDMO (Contract Development and Manufacturing Organization) for both the Canadian and international markets. Thanks to substantial investments totaling $150 million, we have tripled our sterile injectable capacity, enabling us to provide a comprehensive range of services for prefilled syringes, liquid vials, and lyophilized vials. We eagerly look forward to connecting with you, whether in person or through the partnering app! | Since 1983, Pharmascience has been a leading manufacturer of generic, branded, and over-the-counter pharmaceuticals, serving both the Canadian and international markets. With product distribution in over 50 countries, we provide more than 1,400 different high-quality products to pharmaceutical wholesalers, hospitals, and pharmacists. Our facilities produce more than 5 billion dosage units of medicines every year.
PatSnap
Patsnap empowers IP and R&D teams by providing better answers, so they can make faster decisions with more confidence. Founded in 2007, Patsnap is the global leader in AI-powered IP and R&D intelligence. Our domain-specific LLM, trained on our extensive proprietary innovation data, pairs seamlessly with our AI assistant, Hiro, to deliver insights that drive results—boosting IP productivity by 75% and cutting R&D wastage by 25%. IP and R&D teams collaborate better with a user-friendly platform across the entire innovation lifecycle. Over 15,000 companies trust Patsnap to innovate faster with AI, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini. | Founded in Singapore in 2007, PatSnap is a global leading innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, PatSnap empowers IP and R&D teams to unlock insights, accelerate discoveries and protect breakthroughs. Trusted by more than 15,000 enterprises, law firms and research institutions in over 50 countries including one-third of the world’s largest R&D spenders, Patsnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.
Parque Pharma / Helix
PARQUE PHARMA + HELIX Where Infrastructure Meets Execution In life sciences, speed, compliance, and control often conflict. Companies must choose: build and wait years, outsource and lose visibility, or buy risk. These tradeoffs drain capital, erode margin, and delay impact. Parque Pharma and Helix eliminate that tradeoff. We offer a single-entry platform into Mexico and Latin America—combining GMP-ready infrastructure and regulatory-commercial execution in one seamless model. Two Forces. One Outcome. Parque Pharma Mexico’s first and only pharmaceutical condominium model, delivering turnkey, validated GMP facilities with shared infrastructure. No CapEx. No permitting delays. Just speed, certainty, and full regulatory alignment (COFEPRIS, FDA, EMA, USDA). Helix A strategic execution system for health, designed to compress timelines and reduce friction. From product registration to facility activation and market expansion, Helix integrates regulation, operations, and commercial logic. Together, we make GMP execution plug-and-play. What We Offer GMP facility leasing (with option to buy) COFEPRIS / FDA / EMA regulatory navigation Product registration and local compliance GMP validation & audit readiness Licensing, M&A support, and market launch Operational strategy for long-term scaling Why It Works Speed to Market Installations ready in 10 months or less—with fast-track validation pathways. Regulatory Clarity Certified cleanrooms. No licensing delays. No retrofit risk. Zero CapEx, Maximum Flexibility Lease Class A, spec-built facilities designed for pharma, biotech, supplements, and veterinary use. Execution Certainty Validated systems. Turnkey delivery. Compliance built-in. Ideal For… Biotech companies expanding into Latin America Pharma looking to escape CMO bottlenecks Brands needing dual COFEPRIS + SENASICA certification Supplement companies requiring FDA-grade local ops CDMOs seeking flexible GMP-certified space Let’s Connect at BIO 2025 If you’re scaling in Mexico or LatAm— Let’s turn compliance and construction into momentum.
OcyonBio
OcyonBio is a game-changing company that offers an innovative solution to the challenges faced by life science organizations in manufacturing and development. We provide dedicated autonomous manufacturing capacity, along with an interconnected infrastructure and cutting-edge systems, to support every stage of the product lifecycle—from early development and pre-clinical phases to clinical trials and commercial production. Unlike traditional approaches, OcyonBio operates as a next-generation cGMP incubator space, boasting a comprehensive range of regulatory capabilities and abundant resources. Our goal is to empower our partners with the necessary tools and support to generate critical CMC data, facilitating smooth and efficient regulatory applications. With OcyonBio, companies can bid farewell to the costly and time-consuming process of building their own facilities. We offer a flexible solution that safeguards intellectual property, streamlines project schedules, optimizes resource allocation, and minimizes the risks associated with new product introduction. By eliminating the need for expensive infrastructure, we reduce overall costs, freeing up resources that can be allocated towards research, development, and innovation. Our manufacturing and development spaces are carefully designed to operate autonomously, ensuring maximum efficiency and productivity. At the same time, they remain interconnected with essential systems to meet the clinical and commercial requirements of our partners. This interconnectedness enables seamless collaboration and information flow, further enhancing the success of your projects. Partnering with OcyonBio means gaining access to a state-of-the-art facility without the burden of construction costs, while enjoying the flexibility to adapt and scale operations according to your needs. We empower you to focus on what matters most—advancing your life science initiatives—while we take care of the manufacturing and development processes. Experience the future of manufacturing and development with OcyonBio. Together, we will revolutionize the life sciences industry, unlocking new possibilities and achieving groundbreaking results. Contact us today to embark on a transformative journey towards success. | OcyonBio redefines innovation in life sciences manufacturing and development. Our tailored solutions address key industry challenges, offering dedicated autonomous manufacturing capabilities and a seamlessly integrated infrastructure. By covering every stage of the product lifecycle, from early development to commercial production, we streamline the path to market success. As pioneers of next-generation cGMP incubator spaces, OcyonBio provides expansive regulatory expertise and abundant resources. Our mission is to equip our partners with essential tools for generating critical CMC data, ensuring efficient regulatory submissions. Choose OcyonBio and say goodbye to the burdens of constructing your own facilities. Our flexible, secure solutions protect intellectual property, enhance project timelines, and optimize resource use, all while minimizing risk during new product introductions. Our approach not only cuts costs but also reallocates savings to foster further research, development, and innovation. Our facilities are designed for peak efficiency and productivity, maintaining connectivity with vital systems to support both clinical and commercial demands. This integration fosters unparalleled collaboration and information exchange, propelling your projects forward. By partnering with OcyonBio, you gain access to cutting-edge facilities without the overhead of construction costs, coupled with the agility to scale operations as needed. Focus on advancing your initiatives; we’ll handle the complex manufacturing and development logistics. Discover the future of life science manufacturing with OcyonBio. Join us in revolutionizing the industry, unlocking new possibilities, and achieving extraordinary outcomes. Contact us today to start your transformative journey toward success. | OcyonBio – Empowering Innovation in Advanced Therapies Headquartered in Aguadilla, Puerto Rico, OcyonBio is a next-generation contract development and manufacturing organization (CDMO) specializing in the development and commercial manufacturing of biologics, cell and gene therapies (CGT), and aseptic drug products. With a foundation built on flexibility, speed, and regulatory excellence, OcyonBio provides integrated solutions for companies developing complex, life-saving therapies. Our Mission To enable biotechnology innovators to bring breakthrough therapies to market faster and more efficiently by providing world-class infrastructure, tailored contract development and manufacturing organization (CDMO) services, and a unique partnership model that empowers scientific teams. Our Services OcyonBio offers a comprehensive suite of services to support the entire development lifecycle: 1. Biologics and CGT Manufacturing • Cell Therapy: Autologous and allogeneic platforms, including CAR-T, TCR, and stem cell-based therapies. • Gene Therapy: Viral vector production (AAV, LV), plasmid DNA production, and fill-finish. • Biologics Drug Substance Manufacturing: Monoclonal antibodies and other recombinant proteins produced using mammalian expression systems (e.g., CHO). • GMP Suites: Modular, BSL-2 compliant cleanroom spaces for Phases I–III and commercial production. 2. Aseptic Fill & Finish • State-of-the-art isolator-based systems for vial and syringe filling. • Flexible batch sizes support clinical through commercial-scale products. 3. Analytical Development & Quality Control • Custom assay development for identity, purity, potency, and safety. • In-house microbiology, molecular biology, and biochemical analytics. • Stability studies, method validation, and release testing. 4. Regulatory & Quality Support • Full cGMP compliance under FDA and EMA guidelines. • Support for IND, IMPD, and BLA submissions. • Quality-by-Design (QbD) implementation and risk-based validation strategies. 5. Development & Technology Transfer • Process development and scale-up from R&D to GMP. • Tech transfer frameworks that minimize risk and timelines. • Collaborative team integration between client scientists and OcyonBio experts. Flexible Infrastructure Model OcyonBio offers a hybrid model that combines the benefits of a Contract Development and Manufacturing Organization (CDMO) with the autonomy of dedicated, client-operated space. Companies can lease customizable GMP suites, QC labs, and support areas within our purpose-built campus while accessing centralized services such as: • Centralized QA/QC and regulatory support • Supply chain and cold chain management • Utilities, warehousing, and environmental monitoring • Trained labor pool and technical assistance This unique model accelerates facility readiness while preserving control over critical manufacturing processes. Facilities OcyonBio’s 200,000+ square-foot campus in Aguadilla includes: • ISO 7/ISO 8 cleanrooms • Dedicated vector production suites • Aseptic filling lines with isolator technology • Analytical and QC laboratories • Office and training space for client teams • Modular expansion zones to meet growing capacity needs Puerto Rico offers a strategic geographic and regulatory advantage: U.S. jurisdiction, cost-effective labor, strong logistics, and significant tax incentives. Why Partner with OcyonBio? • Speed to Clinic and Market: Accelerated timelines through modular buildouts and technology transfer expertise. • Customized Engagement Models: From comprehensive CDMO services to co-located manufacturing partnerships. • Deep Expertise: Decades of experience across regulatory, operations, process development, and manufacturing. • Resilient Supply Chain: On-island capabilities minimize international shipping risks and ensure control over the supply chain. • Incentivized Operating Environment: Leverage Puerto Rico’s Act 60 incentives, workforce development programs, and export advantages. Your Partner from Discovery to Commercialization Whether you’re a biotech startup advancing a first-in-human product or an established biopharma seeking a strategic CGT manufacturing partner, OcyonBio offers the agility, infrastructure, and scientific depth to bring your innovations to life. Join us at BIO 2025 to explore how OcyonBio can support your next breakthrough.
Neolpharma
Neolphama is a Mexican Pharmaceutical Corporation, made up of different specialized business units dedicated to research and development of high quality drugs contributing to better human health. | Top Mexican Pharma company, with presence in over 14 countries throughout the LATAM region.
Midas Pharma
One Partner – many Opportunities. Midas Pharma is a mid-sized pharmaceutical company, founded 1988 and based in Ingelheim, Germany. Midas offers products, services and expertise along the entire pharmaceutical value chain – from Starting Materials and Active Pharmaceutical Ingredients to market-ready Finished Products and Devices. Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. With more than 270 employees and 10 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts and well-established networks in different pharmaceutical sectors. Visit Midas Pharma at the German Pavilion and www.midas-pharma.com | Accelerate your development of Biologics and Drug Device Combinations and benefit from the experience and comprehensive pharmaceutical support to safeguard your project executions – from pre-clinic to commercial phase. Benefit from our experience and our wide-ranging portfolio, from cell-line development, CDMO, QM, RA, PV, QP, MA holder and supply chain management service, to complete your projects. Resilience your supply chains with our broad portfolio of biopharmaceutical ingredients and drug substances from R&D to commercial supply, as natural & unnatural Amino-acids, building blocks for Nucleic Acids (Nucleotides, Cap-analogues and Phosphoramidites) as well as Linkers & Payloads for drug conjugates. Ask us also about our customized solutions. Multiply your licensing opportunities for innovative developments. | Where innovation meets expertise – Midas Pharma is your all-in-one provider for biopharma Accelerate your development of Biologics and Drug Device Combinations and benefit from our expertise and tailored pharmaceutical support to safeguard your project executions – from drug discovery to commercial phase. Focus on your specific demands, whether it’s optimizing capacity or importing your product into the European Union, by using our pharma infrastructure: EU QP release services (in-house QPs), regulatory support incl. marketing authorization holdership and pharmacovigilance services (in-house EU-QPPV). Exploit our wholesale and supply chain expertise to import, launch and distribute your biopharmaceutical products. Speed up your drug discovery and development with our comprehensive bioanalytical services for mAbs, ADCs, peptides, and nucleic acids. We offer a wide range of cutting-edge analytical methods, e.g., for structural and functional characterization of proteins, lead & clone selection, and biosimilar studies. Resilience your supply chain with our broad portfolio of biopharmaceutical intermediates (Building blocks for TIDES, Linkers & Payloads etc.), produced at GMP-compliant sites. Discover Gx Inbeneo®, our next generation autoinjector, which addresses the challenges of subcutaneous self-administration of biopharmaceuticals with injection volumes of up to 3 ml and ultra-high viscosities. The constantly pre-pressurized system ensures smooth continuous injection with shortened injection times; a needle that is not in contact with the drug product prevents needle clogging. Gx Inbeneo® offers quick customization to different formulations for faster time-to-market. Midas Pharma advantages: – All-in-one provider with modular service offers, tailored to your needs – Collaboration from expert to expert – EU headquartered, with a global operational footprint | With more than 35 years of experience, Midas Pharma brings proven expertise to every stage of the biopharmaceutical product life cycle. As a fully-fledged pharmaceutical company with EU GMP/GDP/WDA and MIA licenses, we offer a complete and reliable infrastructure tailored to your needs, whether you are an innovative start-up or an established biopharmaceutical company. Combining scientific expertise with a robust global network, Midas Pharma delivers integrated end-to-end solutions that accelerate your path from early-stage R&D to market. We provide the insight, infrastructure, and commitment needed to achieve your goals with confidence and to succeed in the competitive biopharmaceutical landscape. Your key benefits: • Process development: Expertise in biotechnological and chemical processes, covering preclinical development to commercial manufacturing. • Analytical services: Comprehensive structural and functional analysis that delivers precise insights into your molecule; tailored solutions, aligning technical accuracy with strategic goals through a holistic approach. • Starting materials, intermediates, drug substance, drug product, fill and finish (non GMP and GMP quality): Robust supply chain, including documentation in compliance with the authority requirements worldwide. • Novel autoinjector platform: Innovative solutions that overcome key challenges in subcutaneous delivery – enabling the injection of small and large volumes, especially but not only for high concentrated biologics. • GMP services: From EU QP release to global import/export: guaranteeing your products meet all regulatory standards. • Market entry strategy: Guidance through the process of entering target markets, including due diligence and clinical trials. • Business Development Advisory Services: With our global network spanning mid‑ and top‑tier biopharma in the US, Europe, and Asia, we deliver expert advisory support to accelerate your partnering success. Our customized services include financial modeling and valuation, deal structuring, due diligence, partner identification, and contract negotiation empowering you to maximize shareholder value. • Commercial operations: Comprehensive wholesale solutions along with marketing authorization holder (MAH) and pharmacovigilance (PV) services. Analytical services powered by Biofidus – A member of the Midas Group
MIAS Pharma Ltd
MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU regulations. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provide oversight of: – European Qualified Person (QP) services – Regulatory compliance of manufacturing activities – Regulatory compliance of Repackaging / Relabeling services – Regulatory compliance of Shipment and Transportation activities – Compliance with responsibilities as a Market Authorisation Holder (MAH) MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients’ requirements. | MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Primary customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU / UK regulations. In recent times MIAS also supports CMOs, CROs, Packaging companies and Testing companies QP solutions to take the burden off internal resources. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provides: 1. European & UK Qualified Person (QP & QA) services 2. QP Audit programs 3. QMS Design: WDA & MIA 4. Turnkey EU Launch solutions: Packaging, Labelling, Distribution & Testing (Via Alliances) 6. Support for IMPD and Market Authorisation (MA) submissions MIAS operates in a hub and spoke model with a core group of MIAS employees being able to rely on a group of international associates to flex up/down capacity depending on clients requirements. | MIAS Pharma Supports Companies to carry out both Clinical Studies and Commercial Product launches in Europe and the UK. We hold licences known as MIA’s which allow us to import and QP release your products. As part of our service offering we can support you with: – EU / UK set-up – We can support your IMPD / MA submissions – Via our partner companies we can support Market Access, commercialisation and Distribution – QP Release – Product testing and retains – Audit Programs – WDA and RP Services
Mexico
Mexico is an upcoming global player in the biotech industry, with over 3,500 biotech companies across the country, coupled with strong academic institutions and groundbreaking research centers.
Mediclone Biotech Private Limited
Mediclone Biotech is a Biotech company specializing on Immuno biotechnology under the ambit of Medical Biotechnology. It was started in 1995 in Chennai as a maiden biotech venture by first-generation entrepreneurs. As of today, Mediclone has more than 1,00,000 Square feet of infrastructure comprising Therapeutics and Diagnostics manufacturing facility. Driven by a passion for innovation and excellence, Mediclone Biotech integrates the latest advancements in biotechnology with rigorous scientific research to deliver high-quality solutions that improve patient outcomes. The company’s R&D facilities are equipped with state-of-the-art technologies and staffed by highly skilled scientists and researchers, enabling the development of next-generation products that meet the highest standards of efficacy and safety. Mediclone Biotech continues to grow on its R&D foundation, it takes the necessary steps toward ensuring scalability and production consistency by transitioning into Good Manufacturing Practices (GMP). Mediclone biotech is committed to advancing in the fields of diagnostics, therapeutics, and life sciences. The company’s dedicated R&D team continuously works on discovering and creating novel molecules, cutting-edge diagnostic kits, and medical devices to address unmet medical needs across the globe. GMP compliance is central to the company’s mission, as it ensures that products are manufactured with the highest quality standards, reliability, and safety. By adhering to GMP regulations, Mediclone Biotech guarantees that its products meet international standards, ensuring their suitability for clinical and commercial use. Through continuous innovation, research, and GMP-compliant production, Mediclone Biotech strives to be a leading player in the biotech industry, committed to advancing healthcare and improving lives worldwide. Some of the Major Research and Development projects handled by Mediclone Biotech Pvt. Ltd. 1. An alternative technology to anti-snake venom serum using monoclonal Fab2 cocktail – Commercial Scale Manufacturing (Phase-II) in collaboration with Department of Biotechnology, New Delhi, India. 2. Development and Manufacture of Anti-Rabies Monoclonal antibody (MAb) cocktail as Post-exposure prophylaxis in collaboration with Department of Science and Technology (DST), New Delhi, India 3. Development of an Immunodiagnostic MAb for Rabies Virus Detection kit. (In-House) 4. Monoclonal therapeutics to prevent RhD antigen sensitization in hemolytic disease of the newborn (HDN). (In-House) 5. Role of MC1A Gene in the Pathogenesis of Mycobacterium Tuberculosis – Specific approach Using Monoclonal Antibodies in collaboration with Public Health England, U.K. 6. MOA signed with Beckton Dickson, USA – Monoclonal Antibody manufacturing for six different molecules of various Therapeutic Antigens.
Marjan Farma
We are a Brazilian pharmaceutical company with more than 60 years of history focused on offering health products to improve people’s quality of life and well-being. | Founded in 1961, Marjan Farma has been a trusted pharmaceutical industry for the past 62 years, developing, producing and marketing innovative products to improve patient health and well-being. | Founded in 1961, Marjan Farma has been a trusted pharmaceutical industry for the past 64 years, developing, producing and marketing innovative products to improve patient health and well-being.